Shots:
Zonsen PepLib Biotech has entered into a worldwide R&D and license agreement with Eli Lilly to jointly advance peptide-based drug candidates using PepLib’s robust & diverse peptide libraries & discovery platforms
As per the deal, PepLib will screen & identify optimal peptide molecules using its in-house platform, while Lilly will oversee IND-enabling activities, clinical…
Shots:
CSPC has entered a strategic collaboration & license deal with AZ to develop long-acting peptides, using CSPC’s sustained-release delivery tech platform & AI-driven peptide drug discovery platform
As per the deal, the Group will collaborate with AZ on novel peptide discovery & long-acting delivery, while AZ will gain exclusive global rights (excl. Greater China)…
Zonsen PepLib Biotech Grants Novartis Global License for Radioligand Therapy Asset with $50M Upfront
Shots:
Zonsen PepLib Biotech has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based radioligand therapy asset
As per the deal, Novartis will obtain exclusive worldwide rights & lead the development & commercialization activities for the undisclosed asset
In return, PepLib will receive $50M upfront, with additional development, regulatory, & sales milestone payments,…
Day 1 Breakdown
The #PCG2025 Symposium commenced on an inspiring note, setting the stage for two days of insightful discussions, collaborations, and knowledge exchange.
Opening Session
Dr. Ratnesh Jain, Founder & Director, Mumbai Cluster, delivered the inaugural address, sharing his vision of bringing together pharma professionals, R&D experts, CXOs, and academicians to accelerate advancements in…
The Mumbai Biocluster, an initiative of the Institute of Chemical Technology (ICT), Mumbai, and operated as a Section-8 non-profit organization, proudly announces the inaugural edition of the Peptides & Complex Generics Symposium (PCG 2025).
This landmark gathering, set to take place on 25–26 September 2025 at The Lalit, Mumbai, aims to spotlight India’s growing role…
Shots:
Cyprumed & Merck have entered into a non-exclusive license & option agreement to develop oral formulations of Merck’s peptides, leveraging Cyprumed’s innovative drug delivery techÂ
As per the deal, Merck has secured non-exclusive global rights to Cyprumed’s oral peptide delivery platform for an undisclosed number of targets, with an option to exclusively license it…

